MARKET

XOMA

XOMA

Xoma Corp Del
NASDAQ
26.09
+0.27
+1.05%
Closed 16:02 04/23 EDT
OPEN
26.48
PREV CLOSE
25.82
HIGH
26.79
LOW
25.82
VOLUME
11.78K
TURNOVER
0
52 WEEK HIGH
27.00
52 WEEK LOW
13.48
MARKET CAP
303.56M
P/E (TTM)
-6.4635
1D
5D
1M
3M
1Y
5Y
*AnaptysBio Names Thomas Smart as CEO >ANAB
Dow Jones · 11h ago
Press Release: Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics Appoints Thomas Smart as CEO of a new drug modality to treat solid tumors. Mr. Smart has 25 years of experience in senior management and executive roles across the biopharmaceutical industry. Actym's lead candidate, ACTM-838, will enter clinical evaluation later this year.
Dow Jones · 11h ago
Day One wins FDA nod brain cancer therapy, Ojemda
Day One Biopharmaceuticals’ lead candidate tovorafenib for a type of pediatric brain cancer called low-grade glioma. The treatment branded as Ojemda will be indicated in the U.S. For children with relapsed or refractory pediatric gliomas. XOMA (NASDAQ:XOMA) received a $5M milestone payment after the decision.
Seeking Alpha · 1d ago
Weekly Report: what happened at XOMA last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at XOMA last week (0408-0412)?
Weekly Report · 04/15 11:40
Weekly Report: what happened at XOMA last week (0401-0405)?
Weekly Report · 04/08 11:45
*News On Kinnate Biopharma Inc. (KNTE) Now Under XOMA
Dow Jones · 04/03 21:08
XOMA CORPORATION ANNOUNCES CLOSING OF TENDER OFFER
Reuters · 04/03 13:00
More
About XOMA
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Webull offers XOMA Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.